3SBio Inc
HKEX:1530
3SBio Inc
HKEX:1530
Price:
23.22
HKD
-3.73%
Market Closed
Market Cap:
HK$56.5B
Relative Value
The Relative Value of one
3SBio Inc
stock under the Base Case scenario is
14.95
HKD.
Compared to the current market price of 23.22 HKD,
3SBio Inc
is
Overvalued by 36%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
14.95
HKD
Overvaluation 36%
Multiples Across Competitors
Competitors Multiples
3SBio Inc Competitors
3SBio Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
3SBio Inc
HKEX:1530
|
54.8B HKD | 5.4 | 20.7 | 14.5 | 17.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
389.4B USD | 6.5 | 165.9 | 16.1 | 22.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197B USD | 5.4 | 25.5 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.8B USD | 6.7 | 23.9 | 16.3 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.6B USD | 10 | 31.8 | 23.3 | 24.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.4B USD | 5.7 | 18.2 | 13.7 | 15.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
74.1B AUD | 3.3 | 17.2 | 11.8 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43B EUR | 14.3 | 33.6 | 57.3 | 58.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
